Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Metabolic control and sex: A focus on inflammatory-linked mediators

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ovariectomy reduces vasocontractile responses of rat middle cerebral arteries after focal cerebral ischemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Eloísa Rubio-Beltrán
  • Alejandro Labastida-Ramírez
  • Kristian A Haanes
  • Antoon van den Bogaerdt
  • Ad J J C Bogers
  • Eric Zanelli
  • Laurent Meeus
  • A H Jan Danser
  • Michael R Gralinski
  • Peter B Senese
  • Kirk W Johnson
  • Joseph Kovalchin
  • Carlos M Villalón
  • Antoinette MaassenVanDenBrink
Vis graf over relationer

BACKGROUND AND PURPOSE: Triptans are 5-HT1B/1D receptor agonists (that also display 5-HT1F receptor affinity) with antimigraine action, contraindicated in patients with coronary artery disease due to their vasoconstrictor properties. Conversely, lasmiditan was developed as an antimigraine 5-HT1F receptor agonist. To assess the selectivity and cardiovascular effects of lasmiditan, we investigated the binding, functional activity, and in vitro/in vivo vascular effects of lasmiditan and compared it to sumatriptan.

EXPERIMENTAL APPROACH: Binding and second messenger activity assays of lasmiditan and other serotoninergic agonists were performed for human 5-HT1A , 5-HT1B , 5-HT1D , 5-ht1E , 5-HT1F , 5-HT2A , 5-HT2B , and 5-HT7 receptors, and the results were correlated with their potency to constrict isolated human coronary arteries (HCAs). Furthermore, concentration-response curves to lasmiditan and sumatriptan were performed in proximal and distal HCA, internal mammary, and middle meningeal arteries. Finally, anaesthetized female beagle dogs received i.v. infusions of lasmiditan or sumatriptan in escalating cumulative doses, and carotid and coronary artery diameters were measured.

KEY RESULTS: Lasmiditan showed high selectivity for 5-HT1F receptors. Moreover, the functional potency of the analysed compounds to inhibit cAMP increase through 5-HT1B receptor activation positively correlated with their potency to contract HCA. In isolated human arteries, sumatriptan, but not lasmiditan, induced contractions. Likewise, in vivo, sumatriptan decreased coronary and carotid artery diameters at clinically relevant doses, while lasmiditan was devoid of vasoconstrictor activity at all doses tested.

CONCLUSIONS AND IMPLICATIONS: Lasmiditan is a selective 5-HT1F receptor agonist devoid of vasoconstrictor activity. This may represent a cardiovascular safety advantage when compared to the triptans.

OriginalsprogEngelsk
TidsskriftBritish Journal of Pharmacology
Sider (fra-til)epub
ISSN0007-1188
DOI
StatusUdgivet - 1 jan. 2019
Eksternt udgivetJa

Bibliografisk note

© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

ID: 58349061